RESEARCH TEAM

  • Curtisha Charles
  • Julius Esguerra

Office:
(410) 550-9080

Email: idresearch@jhmi.edu

 

STAY CONNECTED

Twitter You Tube

Research

We are currently recruiting for the following active studies:

Skin Microbiome Study

Understanding the Skin Microbiome Through the Integration of Metagenomics, Bioinformatics, Spatial Ecology, and Synthetic Biology

This research is being done to gather information and learn more about the function of skin microbial ecosystems. For this, we will conduct fine-scale sampling of the human skin microbiome and collect information regarding environmental and behavioral variables that might influence skin microbial composition.

In addition, we seek methods for ‘remote sensing’ of the skin microbiome. To achieve this, we will require GC/MS data that can then be correlated with the types of microbes in a person’s microbiome.

Contact:
Curtisha Charles
ccharle8@jhmi.edu
(410) 550-1131

Principal Investigator
Jonathan Zenilman, MD

 

C diff Drug Study

A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum Microbiota™ (CP101) in Subjects with Recurrence of Clostridium difficile Infection.

The purpose of this research study is to evaluate potential side effects and effectiveness of taking a single dose (10 capsules) of an investigational study drug called CP101 in preventing the next episode of Clostridium difficile infection (CDI).

CP101 is an investigational drug. The word "investigational" means CP101 is not approved by the U. S. Food and Drug Administration (FDA) and is still being tested in research studies. However, the FDA is allowing the use of CP101 in this study.

Clostridium difficile is a type of bacteria, which lives in the intestines of many people and is also present in the environment in places such as soil and water. Diarrhea, the most common symptom of a CDI, may be caused by the use of some antibiotic therapies causing a change to the normal balance of the microflora (a complex community of naturally occurring bacteria that live in your intestines). When the intestinal microflora is out of balance, the Clostridium difficile bacteria begin to grow and produce toxins, causing frequent diarrhea and other symptoms such as abdominal pain or tenderness, loss of appetite, low-grade fever, nausea and vomiting.

In this study, the effects of CP101 will be compared with a placebo. A placebo is an inactive material that does not contain any active study drug. By comparing people's responses to the placebo and to CP101, researchers can tell whether CP101 is having any benefit. When we talk about “study drug” we are talking about both the placebo and CP101.

Contact:
Curtisha Charles
ccharle8@jhmi.edu
(410) 550-1131

Principal Investigator:
Jonathan Zenilman, MD

 

C diff Vaccine Study

A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER - B5091007

The purpose of this study is to find out if an investigational vaccine prevents severe diarrhea caused by a germ (bacterium) called Clostridium difficile (C diff). Vaccines help your body to make antibodies which help to fight against diseases (this is also called an immune response).

C diff is a significant cause of infectious diarrhea. Its severity can range from being mild to severe, and can lead to death. Most people who get C diff diarrhea are older and:

• Have hospital stays, or;
• See their doctor often, or;
• Live in a nursing home, or;
• Take antibiotics.

People 50 years or older who meet one or more of these criteria are being asked to take part in this study.

This study will compare the effects of a C diff vaccine (PF-06425090) against a placebo to prevent C diff diarrhea. The use of the C diff vaccine in this research study is investigational. The word “investigational” means that the C diff vaccine is not approved for marketing by the Food and Drug Administration (FDA). The FDA is allowing the use of the C diff vaccine in this study. A placebo looks like the investigational vaccine, but does not have any active ingredients in it. For this study, the placebo will be salt-water (also known as normal saline).

In this study, participants will receive three injections over a period of 6 months. We will closely monitor participants for signs of infection for up to 3 years after receiving the last vaccine. We will also collect information on any side effects the C diff vaccine might cause and general health.

Contact:
Curtisha Charles
ccharle8@jhmi.edu
(410) 550-1131

Principal Investigator:
Geeta Sood, MD

 

Vaginal Microbiome Study

Recurrent Bacterial Vaginosis: Microbiota Responses to Hormonal Contraception

Recurrent Bacterial Vaginosis (BV) (1 or more episodes per year) is an important cause of vaginal symptoms in women and is often difficult to treat. Hormonal contraception (HC), (birth control pills, patches, vaginal hormonal rings, implants, IUDs or Depo Provera shots) may affect the normal bacterial communities of the female reproductive tract (vaginal microbiota). Some women with recurrent BV who use Hormonal Contraception may experience fewer episodes of BV. Others may not, but we don’t yet know why. We want to better understand how HC impacts the bacterial communities of the female reproductive tract in women with recurrent BV, in order to understand how to better treat BV.

To gather this information, we want to follow women with recurrent BV (1 or more episodes per year) who are thinking of starting or stopping Hormonal Contraception. We hope you consider being one of these women!

For more information or to enroll, please contact us at 443-909-6954 or email HCLStudy@jhmi.edu.

Eligibility, Participation & Enrollment »

Contact:
Curtisha Charles
ccharle8@jhmi.edu
(410) 550-1131

Principal Investigator:
Susan Tuddenham, MD MPH